A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

Trial ID or NCT#

NCT01667419

Status

not recruiting iconNOT RECRUITING

Purpose

This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 will include participants with completely resected Stage IIC, IIIA (participants with one or more nodal metastasis greater than [>] 1 millimeter [mm] in diameter), or IIIB cutaneous melanoma, as defined by the American Joint Committee on Cancer (AJCC) Classification, Version 7; Cohort 2 will include participants with Stage IIIC cutaneous melanoma, as defined by this classification scheme. Within each cohort, participants will be randomized (1:1 ratio) to receive vemurafenib or matching placebo over a 52-week period.

Official Title

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Histologically confirmed melanoma of cutaneous origin - Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been completely resected - BRAF V600 mutation status of the current primary tumor or involved lymph node determined to be positive using the cobas BRAF V600 mutation test - Surgically rendered free of disease within 90 days of randomization - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Life expectancy of at least 5 years - Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment - Adequate hematologic, hepatic, and renal function
Exclusion Criteria:
  1. - History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of melanoma, including interferon alpha-2b and pegylated interferon alpha-2b - History of limb perfusion therapy - History of radiotherapy for the treatment of melanoma - Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatment - Family history of inherited colon cancer syndromes - Known personal history of >3 adenomatous colorectal polyps or a personal history of adenomatous colorectal polyp(s) >2 centimeters (cm) in size - History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions - History of or current clinical, radiographic, or pathologic evidence of recurrent lymph node involvement after resection of a primary melanoma with lymph node involvement at any time in the past - History of local and/or regional and/or distant melanoma recurrence - History or current radiographic or pathologic evidence of distant metastases - History of clinically significant cardiac or pulmonary dysfunction - Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study treatment - Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus

Investigator(s)

Susan M. Swetter, MD
Susan M. Swetter, MD
Dermatologist, Dermatologic oncologist, Cutaneous oncology specialist, Melanoma specialist
Professor of Dermatology
Sunil Arani Reddy
Sunil Arani Reddy
Medical oncologist, Cutaneous oncology specialist
Clinical Assistant Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061